Literature DB >> 26276838

Thoracic endovascular repair first for extensive aortic disease: the staged hybrid approach†.

Alessandro Vivacqua1, Jay J Idrees1, Douglas R Johnston1, Edward G Soltesz1, Lars G Svensson1, Eric E Roselli2.   

Abstract

OBJECTIVES: Repair of extensive aortic disease carries a significant risk of death and morbidity, the most feared complication being spinal cord ischaemia. Objectives of this study are to characterize patients, describe repair methods and assess feasibility and safety of hybrid staged repair for treatment of extensive aortic disease.
METHODS: From to 2001 to 2013, 22 patients underwent extensive aortic repair that included a thoracic endovascular aortic repair (TEVAR) first followed by an open completion repair extending through the visceral and infrarenal aorta for degenerative aneurysm and dissection. At the time of initial repair, all patients were deemed to be at a high risk for conventional open repair and had extensive disease. Indications for open completion included emergency failure of TEVAR (n = 3), early two-stage approach (n = 6) and delayed disease progression after TEVAR (n = 13). The median interval between stages was 6.5 months. The mean age was 56 ± 14 years, 5 patients had connective tissue disorder and the mean maximum aortic diameter was 58 ± 16 mm preoperatively.
RESULTS: There was no death or major complication after initial TEVAR, but the operative mortality rate was 9% (n = 2) after the open procedure. One of these patients died from intraoperative myocardial infarction during emergency repair, and the other had disseminated intravascular coagulation during delayed repair for disease progression after TEVAR. Other complications included paralysis in 1 (4.5%), tracheostomy in 2 (9%) and dialysis in 1 (4.5%), and there was 1 reoperation for bleeding (4.5%). The median follow-up was 37 (range 3.3-93) months and there were no late deaths. There were four late reoperations for proximal disease progression leading to Type 1 endoleak (n = 2), Type A dissection (n = 1) and root aneurysm (n = 1).
CONCLUSIONS: Use of a TEVAR-first approach in combination with a staged open repair is a safe and feasible treatment strategy for repair of extensive aortic disease. A staged hybrid approach to aortic repair in patients at high risk for total aortic replacement may limit morbidity.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Chronic dissection; Elephant trunk; Endovascular; Hybrid aortic repair; Thoraco-abdominal aneurysm

Mesh:

Year:  2015        PMID: 26276838     DOI: 10.1093/ejcts/ezv274

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Midterm outcomes of thoracic endovascular repair for uncomplicated type B aortic dissection with double-barrel type.

Authors:  Atsushi Omura; Hitoshi Matsuda; Tetsuya Fukuda; Yoshikatsu Nomura; Ryota Kawasaki; Hirohisa Murakami; Akitoshi Yamada; Kunio Gan; Nobuhiko Mukohara; Junjiro Kobayashi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-04-30

Review 2.  Open aortic surgery after thoracic endovascular aortic repair.

Authors:  Joseph S Coselli; Konstantinos Spiliotopoulos; Ourania Preventza; Kim I de la Cruz; Hiruni Amarasekara; Susan Y Green
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-06-17

3.  Improved outcomes and value in staged hybrid extent II thoracoabdominal aortic aneurysm repair.

Authors:  Robert B Hawkins; J Hunter Mehaffey; Adishesh K Narahari; Amit Jain; Ravi K Ghanta; Irving L Kron; John A Kern; Gilbert R Upchurch
Journal:  J Vasc Surg       Date:  2017-05-31       Impact factor: 4.268

4.  Chronic thoracoabdominal aortic dissection: endovascular options to obliterate the false lumen.

Authors:  Patrick R Vargo; Jean-Luc Maigrot; Eric E Roselli
Journal:  Ann Cardiothorac Surg       Date:  2021-11

5.  Commentary: Double trouble-Thoracoabdominal aortic aneurysm and heart failure.

Authors:  Patrick R Vargo; Francis Caputo; Eric E Roselli; Faisal G Bakaeen
Journal:  JTCVS Tech       Date:  2021-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.